Xytis, a privately-held biotech company based in both the U.S. (Irvine, CA) and Europe (London, England and Nyon, Switzerland) has raised a new round of series B funding. The company specializes in making treatments for patients with central nervous system (CNS) disorders.
The company previously raised a large $24.5 million round in early 2006 when it also announced a merger with Remergent Inc., a company that commercialized drug discoveries licenses from the University of California system.
VentureBeatVentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
- networking features, and more